Preslow (Felodipine) is commonly used for the management of chronic cardiovascular conditions, focusing primarily on controlling blood pressure and easing the heart’s workload. Its core therapeutic indications include hypertension and stable angina pectoris.

Supporting Blood Pressure and Angina Management

This medication is applied across therapeutic domains where additional symptomatic support is needed for conditions involving sustained vascular resistance. It is used to help manage essential hypertension, contributing to the daily control of high blood pressure, and is also relevant for managing symptoms related to chest discomfort or pressure associated with chronic stable angina. Its application is relevant across these two therapeutic domains.

“Felodipine is generally applied in contexts marked by increased vascular tension and is considered relevant when supportive symptom management is appropriate.”

The use of Preslow may assist with reducing the long-term strain on the circulatory system and may contribute to supporting organ health. For patients with angina, it can act as a preventive strategy, contributing to support improved comfort during physical activity.

Quick Fact: Support for Vascular Strain

Preslow is primarily used to address symptoms related to systemic imbalance and organ-specific functional stress that arise from sustained, high resistance in the arteries. Its application may assist with maintaining functional stability through the management of persistent pressure levels.

Preslow (Felodipine) is officially indicated for use in adults for managing high blood pressure (hypertension) and chronic stable angina. Regulatory documentation strictly defines several groups for whom the medicine is restricted or absolutely prohibited.

Absolute Contraindications (Prohibited Use)

The medicine is strictly contraindicated for use in:

• Pregnancy and is not recommended during breastfeeding.
• Patients with severe hepatic impairment (severe liver disease).
• Individuals with known hypersensitivity or allergy to felodipine or any components of the tablet.
• Patients with acute, unstable cardiovascular conditions, including acute myocardial infarction, unstable angina pectoris, or decompensated heart failure.

Conditional and Restricted Use

• Age-Group Eligibility: The safety and effectiveness of Preslow have not been established in the pediatric population (children and adolescents), and use in this group is not recommended. For older adults, treatment is typically initiated using the lowest available dose.
• Organ Function: Patients with mild to moderate hepatic impairment must use the medicine with caution due to the risk of elevated plasma concentrations, necessitating close monitoring. Dose adjustments are generally not required for patients with renal impairment.
• Comorbidities: Use in patients with compromised ventricular function or pre-existing heart failure requires caution, as safety data is limited.

Preslow, which contains the active ingredient perindopril (an Angiotensin-Converting Enzyme or ACE inhibitor), can interact with several other medicines and substances. These interactions can affect how Preslow works, increase the risk of side effects, or impact the effectiveness of other treatments. It is essential to inform your doctor or pharmacist about all prescription, over-the-counter medicines, vitamins, and herbal supplements you are taking.

Key Interactions to Discuss with Your Healthcare Provider

How Preslow Works

Targeted Molecular Blockade

The mechanism of Preslow (felodipine) involves the selective blockade of L-type Voltage-Gated Calcium Channels (L-VGCCs), which are the main biological targets on the membranes of arterial smooth muscle cells. This antagonism prevents the transmembrane influx of calcium ions ( Ca^2+), thereby directly interrupting the fundamental signal required for muscle contraction.

Inhibition of the Vascular Contraction Pathway

The molecular blockade of calcium influx initiates a distinct mechanistic cascade: the reduction in intracellular Ca^2+ suppresses the activity of the enzyme Myosin Light-Chain Kinase (MLCK). This inhibition leads to vascular smooth muscle relaxation (vasodilation), which is the primary tissue-level change governing the drug's activity profile.

Systemic Reduction of Circulatory Resistance

The vasodilation across the arterial system translates the cellular action into a system-level effect: the reduction of Peripheral Vascular Resistance (PVR). The reduction in PVR lowers the cardiac afterload, which represents the overall resistance the heart must overcome to eject blood into circulation.

Preslow, which contains the active ingredient Felodipine, is administered exclusively via the oral route as an extended-release tablet. The prolonged-release mechanism of this formulation requires that the tablets must be swallowed whole with water and must not be crushed, chewed, or divided under any circumstances. The standardized administration schedule is once daily, typically taken in the morning to maintain continuous drug concentration throughout the 24-hour cycle. Intake may occur on an empty stomach or with a light meal that is low in fat and carbohydrates, but a procedural constraint across all uses is the mandatory avoidance of consuming grapefruit or grapefruit juice, as this can affect the absorption of the medicine.

The official dosing regimen is highly standardized for both approved indications. For the management of essential hypertension, the usual starting dose is 5 mg once daily, with the typical maintenance dose ranging from 2.5 mg to 10 mg once daily. For stable angina pectoris, the initial dose is also 5 mg once daily, adjustable to a maximum of 10 mg daily if necessary. Dosage adjustments, or titration, should proceed cautiously and only at intervals of at least two weeks, allowing sufficient time for the full effect to become evident.

Specific dose recommendations apply to certain patient populations. For older adults and individuals with impaired liver function, initiation of therapy should consider the lowest available strength, 2.5 mg once daily. In contrast, dose adjustment is generally not required for patients with impaired kidney function. If a daily dose is missed, the instruction is to omit the forgotten dose and resume the normal schedule the following day, rather than taking a double dose. This medication is designated for long-term therapeutic application.

Research Evidence / Overview of Studies for Preslow

Evidence for Use in Essential Hypertension (High Blood Pressure)

The primary research base for Preslow has explored its use in the context of high blood pressure, a condition characterized by physiological strain or stress on the circulatory system. The evidence largely comes from Randomized Controlled Trials (RCTs) and meta-analyses that consolidate findings across multiple trials, as well as long-term outcome trials. These studies were designed to track changes in a patient's Systolic and Diastolic Blood Pressure (SBP/DBP), and to monitor the occurrence of major cardiovascular events.

Research reports patterns observed in the populations studied, detailing blood pressure measurements over short and extended periods. Long-term trials tracked the incidence and recurrence rates of cardiovascular events, with reporting over periods extending several years. Comparative evidence against the newest classes of blood pressure medications is limited in terms of dedicated, long-duration outcome trials, meaning the results apply only to the populations studied under the specific research conditions.

Evidence for Use in Chronic Stable Angina Pectoris (Chest Discomfort)

Preslow was also evaluated in research exploring the use in Chronic Stable Angina Pectoris, a condition often involving periods of heightened symptoms of physical discomfort. The research included various short-term RCTs that focused on episodic symptom patterns and changes in daily functioning or activity level.

The main outcomes that researchers examined included tracking the frequency of anginal episodes and testing a person's exercise tolerance. Studies generally report how symptoms evolved in the observed groups over intermediate follow-up durations. However, research exploring long-term prevention of major coronary events often draws broader conclusions from the entire Calcium Channel Blocker (CCB) class, and dedicated felodipine-only long-term outcome data in this context is still emerging.

What is Still Uncertain About Preslow Research

While the existing research contributes to the broader evidence landscape, certain areas lack full certainty. Comparative evidence is lacking in some key areas against newer antihypertensive agents. Effectiveness and safety have not been established through adequate research in the pediatric population. Additionally, the results apply only to the populations studied; for highly specific subgroups (especially those with complex, severe comorbidities), the available research is limited.

Common questions about Preslow (FAQ)

Q: Is Preslow safe long-term?

Official product information indicates Preslow may be prescribed for use over a longer period to help prevent the recurrence of depressive episodes in recurrent depression. For chronic use, official information describes the importance of clinical monitoring for potential long-term risks. These potential risks, which are noted in regulatory documents, include abnormal bleeding and hyponatremia (a condition involving low levels of sodium in the blood).

Q: What happens if I drink alcohol with Preslow?

Official product information advises against the use of alcohol while taking Preslow. The product label notes that combining Preslow with alcohol may worsen the potential side effects of the medicine.

Storage Conditions

Preslow (Felodipine Extended-Release Tablets) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The official labeling mandates that the product must be protected from light and moisture and kept in its original container to preserve stability until the expiration date.

Child Safety and Handling

It is an explicit regulatory requirement that the medication must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired Preslow must follow local requirements and pharmaceutical take-back programs, as this is the preferred method. Regulatory guidance generally advises against disposal via wastewater or household waste to prevent environmental contamination.